Overview

Pennycillin Labs built a unified data-analytics layer for pharmaceutical and clinical ecosystems across Asia—bridging a fragmented health-tech market.

Our Approach

Our Partners contributed financial modelling, valuation, and growth structuring expertise. A revenue-linked earn-out aligned founders and investors while protecting downside risk.

Value Creation

• Introduced blockchain-verified audit trails that cut regulatory-compliance cost by 22%.
• Partnered with regional health-tech accelerators to expand platform adoption.
• Embedded ESG-aligned digital-wellness KPIs for early carbon-accounting readiness.

Outcome

ARR grew 2.3× within nine months and valuation rose 75%. Partial exit achieved 2.1× MOIC.

Insight

Pennycillin Labs proved that high-quality data can become a new asset class—turning healthcare transparency into investable alpha.